American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Cartesian Therapeutics, Inc. (RNAC)

$6.18 -3.59% NASDAQ: RNAC · 15-min delayed

FREDERICK, Maryland
Public · NASDAQ: RNAC
75 employees

Visit website Follow

$231.5MMarket cap

$400.0KRevenue · FY2025

-$130.3MNet income

75Employees

RNACNASDAQ

2016IPO

About Cartesian Therapeutics, Inc.

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Type: Public · NASDAQ: RNAC
Employees: 75
IPO date: Jun 22, 2016
Headquarters: 7495 NEW HORIZON WAY
FREDERICK, Maryland 21703
Phone: 301-348-8698
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: RNAC Nasdaq
SEC CIK: 1453687
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Cartesian Therapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/cartesian-therapeutics-inc/"><img src="https://americancompanies.com/badge/cartesian-therapeutics-inc.svg" alt="Cartesian Therapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow Cartesian Therapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $400.0K
Net income: -$130.3M
Total assets: $296.4M
Market cap: $231.5M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: RNAC

$6.18 -3.59%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$5.84 $10.59

52-week range

Market cap: $231.5M
Shares outstanding: 37.5M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jun 22, 2016

Cartesian Therapeutics, Inc. (RNAC) Stock Price

Reported a net loss of $130.3M in FY2025.
Trading 42% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Cartesian Therapeutics, Inc..

Write a review

Newsroom

News about Cartesian Therapeutics, Inc.

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight GlobeNewswire Inc. · 2026-06-02 · positive Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 GlobeNewswire Inc. · 2026-05-26 · positive Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight GlobeNewswire Inc. · 2026-05-18 · positive Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ GlobeNewswire Inc. · 2026-05-12 · positive Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight GlobeNewswire Inc. · 2026-04-15 · positive Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight GlobeNewswire Inc. · 2026-01-14 · positive

News & sentiment via Polygon.io

FAQ

Cartesian Therapeutics, Inc.: frequently asked questions

Is Cartesian Therapeutics, Inc. an American company?

Cartesian Therapeutics, Inc. is a US-based company headquartered in Frederick, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Cartesian Therapeutics, Inc. headquartered?

Cartesian Therapeutics, Inc. is headquartered in Frederick, Maryland, United States.

Is Cartesian Therapeutics, Inc. publicly traded?

Yes — Cartesian Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol RNAC on the NASDAQ.

What does Cartesian Therapeutics, Inc. do?

Cartesian Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore